


The Total Synthesis of Vincamine

Sir:

Vincamine, the antihypertensive and sedative¹ major alkaloid of *Vinca minor* L. (Apocyanaceae) was first isolated and characterized by Schlittler.² Recent degradative experiments³⁻⁸ have established structure I for this compound, with the stereochemistry of the D-E ring junction related to the previously synthesized alkaloid eburnamonine.^{9,10} The synthesis of vincamine has now been accomplished starting from tryptamine (II), which was condensed with dimethyl 3-ethyl-3-formylpimelate (III), b.p. 108–109° (0.03 mm.). *Anal.* Calcd. for C₁₂H₂₀O₅: C, 59.00; H, 8.25. Found: C, 58.88; H, 8.20. The latter was readily obtained by exhaustive alkylation of the pyrrolidine enamine of butyraldehyde¹¹ with methyl acrylate, followed by hydrolysis (45% yield).



The key intermediate lactam ester IVa and its epimer IVb were isolated as a crystalline mixture (53% yield), m.p. 160–182°. *Anal.* Calcd. for C₂₁H₂₆N₂O₃: C, 71.17; H, 7.39; N, 7.90. Found: C, 70.89; H, 7.46; N, 7.59. This was accompanied by a mixture of crystalline lactam acids Va and Vb (37% yield), m.p. 226–240°. *Anal.* Calcd. for C₂₀H₂₄N₂O₃: C, 70.57; H, 7.11; N, 8.23. Found: C, 70.56; H, 7.12; N, 8.16. Hydrolysis of the lactam esters IVa and IVb

with aqueous sodium bicarbonate furnished the lactam acids Va and Vb (quantitative yield), which could be converted back to the methyl esters with diazomethane (quantitative yield). Reaction of the mixture of epimeric lactam esters IVa and IVb with phosphorus pentasulfide gave the individual epimeric thiolactam esters VIa (29% yield), m.p. 163–164°, and VIb (29% yield), m.p. 144–145°, which were readily separated by column chromatography on neutral alumina. *Anal.* Calcd. for C₂₁H₂₆N₂O₂S (VIa): C, 68.07; H, 7.07; N, 7.56; S, 8.66. Found: C, 67.84; H, 6.95; N, 7.38; S, 8.94. *Anal.* Calcd. for C₂₁H₂₆N₂O₂S (VIb): C, 68.07; H, 7.07; N, 7.56; S, 8.66. Found: C, 68.05; H, 7.09; N, 7.42; S, 8.77. Desulfurization of the thiolactams with Raney nickel furnished the amino esters VIIa (54% yield), m.p. 149–150°, and VIIb (54% yield), m.p. 144–145°. *Anal.* Calcd. for C₂₁H₂₈N₂O₂ (VIIa): C, 74.09; H, 8.29. Found: C, 74.13; H, 8.32. *Anal.* Calcd. for C₂₁H₂₈N₂O₂ (VIIb): C, 74.09; H, 8.29. Found: C, 74.20; H, 8.40.

Alternatively, the epimeric mixture of thiolactams could be converted to a mixture of amino esters and this then separated by column chromatography on neutral alumina. By either route one obtained the epimeric compounds in equal amounts. Mercuric acetate oxidation of either amino ester VIIa or VIIb to a didehydro immonium salt with ultraviolet absorption at 250 and 359 m μ and reduction of the immonium salt with sodium borohydride gave a mixture of amino esters VIIa and VIIb. Thus a path is provided for complete conversion of intermediates to either of the epimeric series.

Oxidation of the more rapidly eluted amino ester VIIa with *p*-nitrosodimethylaniline and triphenylmethylsodium, followed by carefully controlled acid treatment, furnished *dl*-vincamine (I, 3% yield), which was identified by comparison with an authentic sample of natural vincamine by exact matching of t.l.c. retention times in multiple adsorption and solvent systems and by infrared solution spectra.

Acknowledgment.—The author thanks Dr. E. Schlittler and Dr. W. I. Taylor, CIBA Pharmaceutical Co., Summit, N. J., for a comparison sample of vincamine and the National Institutes of Health for support through Grant G.M.-09381.

DEPARTMENT OF CHEMISTRY
THE UNIVERSITY OF VERMONT
COLLEGE OF TECHNOLOGY
BURLINGTON, VERMONT

MARTIN E. KUEHNE

RECEIVED MAY 4, 1964

Studies on the Azidoazomethine-Tetrazole Equilibrium¹

Sir:

Treatment of 5-aminotetrazole with acetylacetone^{2a} and reaction of 4,6-dimethyl-2-hydrazinopyrimidine with nitrous acid^{2b,c} have been reported to give the same product, 5,7-dimethyltetrazolo[1,5-*a*]pyrimidine (IA).³

(1) This investigation was supported by funds from the C. F. Kettering Foundation and the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, Contract No. PH-43-64-51.

(2) (a) C. Bulow, *Chem. Ber.*, **42**, 4433 (1909); (b) R. Giuliano and G. Leonardi, *Farmaco (Pavia) Ed. Sci.*, **11**, 389 (1956); (c) Kenzo Shirakawa, Japanese Patent 777 (Feb. 6, 1957); *Chem. Abstr.*, **52**, 4699h (1958).

(3) A. M. Patterson, L. T. Capell, and D. F. Walker, "The Ring Index," American Chemical Society, Washington, D. C., 1960. For a different numbering system see A. M. Patterson and L. T. Capell, "The Ring Index," Reinhold Publishing Corp., New York, N. Y., 1940.

(1) L. Szporny and K. Szász, *Arch. Exptl. Pathol. Pharmacol.*, **236**, 296 (1959).

(2) E. Schlittler and R. Furlenmeier, *Helv. Chim. Acta*, **36**, 2017 (1953).

(3) J. Trojánek, O. Štrouf, J. Holubek, and Z. Čekan, *Tetrahedron Letters*, **20**, 702 (1961).

(4) O. Štrouf and J. Trojánek, *Chem. Ind. (London)*, 2036 (1962).

(5) M. Plat, D. D. Mank, J. Le Men, M. M. Janot, H. Budzikiewicz, J. M. Wilson, L. J. Durham, and C. Djerassi, *Bull. soc. chim. France*, 1082 (1962).

(6) O. Clauder, K. Gesztes, and K. Szász, *Tetrahedron Letters*, **24**, 1147 (1962).

(7) J. Mokry, I. Kompis, and P. Šefčovič, *ibid.*, **10**, 433 (1962).

(8) J. Mokry, M. Shamma, and H. E. Soyster, *ibid.*, **15**, 999 (1963).

(9) M. F. Bartlett and W. I. Taylor, *J. Am. Chem. Soc.*, **82**, 5941 (1960).

(10) E. Wenkert and B. Wickberg, unpublished synthesis presented at the 17th National Organic Chemistry Symposium, Bloomington, Ind., June 25–29, 1961.

(11) M. E. Kuehne, S. J. Weaver, and P. Franz, *J. Org. Chem.*, **29**, 1582 (1964).